• Ovid Therapeutics posted a Q1 net loss of $17 million, or $0.12 per share, versus a loss of $10.2 million, or $0.14 per share, a year earlier.
• Total operating expenses climbed to $17.8 million from $12.6 million, as R&D spending rose to $11.2 million from $6.7 million due to elevated preclinical and clinical activity on OV329 and OV4071.
• Cash, cash equivalents and marketable securities totaled $165.6 million as of March 31, excluding $27.3 million received in April from Series A warrant exercises.
• Initiated Phase 1 dosing of OV4071 in healthy volunteers in May; OV329 showed favorable safety, tolerability and PK at doses up to 9 mg, supporting planned Phase 2 studies including a randomized trial in treatment-resistant focal onset seizures expected to start in Q2.
• Raised $60 million in March PIPE financing and received $53.9 million from full Series A warrant exercises; CEO Meg Alexander said runway is expected to extend into 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120700PRIMZONEFULLFEED9718120) on May 12, 2026, and is solely responsible for the information contained therein.